Abbott has partnered with Flatiron Health to integrate its precision oncology testing portfolio directly into OncoEMR®, Flatiron’s cloud-based electronic medical record platform used widely in oncology practices. The integration enables clinicians to order specialized cancer diagnostics and receive results within their existing workflow, eliminating the need to navigate multiple systems or rely on manual processes that can slow decision-making.
Through the integration, oncologists can order key Abbott tests—including Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard®—directly from a patient’s chart. Test status updates and final results are automatically routed back into OncoEMR, creating a centralized and continuous data flow. This approach reduces administrative friction, minimizes delays associated with external portals, and allows clinicians to move more efficiently from diagnostic testing to treatment planning.
A central objective of the collaboration is to address clinician burnout by simplifying workflows. Oncology care often involves complex coordination of diagnostic testing, and the need to switch between platforms or manage disconnected data sources can create inefficiencies and increase cognitive burden. By embedding these capabilities directly into the EMR, Abbott and Flatiron aim to streamline operations and enable faster, more confident, data-driven clinical decisions.
The integration also plays a strategic role in expanding access to precision medicine beyond academic centers. Flatiron’s network includes more than 1,600 community oncology clinics and 4,700 providers, where the majority of cancer care in the United States is delivered. Embedding advanced genomic and molecular diagnostics into these everyday care settings lowers barriers to adoption and helps bring cutting-edge, personalized treatment approaches closer to patients in local communities.
By combining Abbott’s diagnostic portfolio with Flatiron’s widely used oncology platform, the partnership reflects a broader shift toward connected, point-of-care data ecosystems, where clinical insights are delivered seamlessly within existing workflows. This model is increasingly seen as essential for scaling precision oncology and ensuring that advanced diagnostics translate into real-world improvements in patient outcomes.
